A Phase 3 interventional study of MK0954A, hydrochlorothiazide (+) losartan potassium and Comparator: placebo, losartan, hydrochlorothiazide in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 25 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-02-15.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
The purpose of this study is to evaluate antihypertensive (lowering blood pressure) effectiveness of three combinations of approved study drugs compared to both study drugs being given alone.
The duration of treatment is 3.5 months.
6,687 studies on the registry are indexed under Hypertension; 964 are open to participants now.
This study's enrollment of 840 is above the median of 90 across 4,994 interventional studies indexed under Hypertension.
Browse Hypertension studies →Organon and Co is the lead sponsor of 478 studies on the registry; none are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 17 (81%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Mean trough SiDBP after 8 weeks of treatment
Safety
No study locations are listed for this record.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Organon and Co